hypertrophy. 24 AMPK is also reported to exert a direct vasorelaxing effect in isolated aortic rings. 25 Indeed, AMPKα2 knockout mice (AMPKα2 -/-) are hypertensive exhibiting increased responses to vasoconstrictors. 26 In endothelial cells, AMPKα2 deficiency causes aberrant ER stress resulting in endothelial dysfunction and atherosclerosis in vivo. 17, 18 ER stress is reported to play causative roles in cardiovascular diseases, including diabetes mellitus, atherosclerosis, and heart failure. AMPK is reported to be essential in maintaining ER homeostasis, 27 and AMPK inhibition causes aberrant ER stress in endothelial cells, hepatocytes, 18, 28 and other cell types. 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is reported to cause both endothelium-dependent and endothelium-independent relaxation. 29, 30 Whether ER stress contributes to the initiation and progression of hypertension is unknown. In this study, we found that aberrant ER stress increases phenylephrine (PE)-induced vascular contractility and hypertension, both of which were suppressed by AMPK activation. Conversely, we found that AMPKα2 deletion caused aberrant ER stress, abnormal vascular contractility, and high blood pressure in vivo.
Materials and Methods
The ER stress marker, vascular smooth muscle contractility, and blood pressure were monitored in cultured vascular cells and wildtype (WT) or mice deficient in AMPKα1 or AMPKα2. A full description of materials, animals, and methods used, including cell culture, blood pressure measurement, osmotic pump implantation, organ chamber, and Western blots, can be found in the online-only Data Supplement.
Results

Infusion of Tunicamycin Induces ER Stress in Mouse Aortas In Vivo
Tunicamycin is reported to trigger ER stress in cultured cells. Whether Tunicamycin caused ER stress in mice was unknown. We first determined whether Tunicamycin caused ER stress in vivo. To this end, C56BL/6 wild-type (WT) mice were infused with Tunicamycin (10 pg/g per day) for 7 days. Mouse aortas were isolated for immunohistochemical staining of p-elf2α, spiced XBP-1 (XBP-1s), and KDEL, 3 well-characterized ER stress markers. The staining with p-elf2α, XBP-1s, or KDEL was barely detectable in vehicle-infused WT aortas ( Figure  1A ). However, Tunicamycin infusion markedly increased the levels of p-elf2α, XBP-1s, and KDEL ( Figure 1A) , indicating that Tunicamycin is a potent ER stress inducer in vascular walls. 4-Phenyl butyric acid (4-PBA) is a potent ER chaperone. Infusion of 4-PBA did not alter the levels of p-elf2α, spiced XBP-1, and KDEL ( Figure 1A ) in WT mice. However, 4-PBA markedly reduced Tunicamycin-increased ER stress markers (p-elf2α, XBP-1s, and KDEL) in the aortas ( Figure 1A) .
We further validated the markers of ER stress in Tunicamycin-infused mouse aortas in Western blots. In line with increased immunohistochemical stainings shown in Figure 1A , Tunicamycin infusion markedly increased the levels of p-elf2α and XBP-1s ( Figure 1B) . Consistently, 4-PBA administration ablated Tunicamycin-enhanced levels of p-elf2α and XBP-1s ( Figure 1B ).
Tunicamycin Infusion Increases Systolic and Diastolic Blood Pressures In Vivo
We next evaluated whether Tunicamycin infusion altered systolic (sBP) and diastolic blood pressure (dBP) in mice in vivo. Blood pressure was continuously monitored in vehicleor Tunicamycin-infused mice for 16 days by using telemetry transmitters. Tunicamycin infusion lowered sBP at days 5 to 7 ( Figure 1C ). After this initial reduction, Tunicamycin caused a gradual elevation of sBP from day 7 to 9 ( Figure 1C ). After day 10, sBPs in Tunicamycin-infused mice were significantly higher than those in vehicle-infused mice ( Figure 1C ). sBP in Tunicamycin-treated mice reached maximal at day 13 and remained elevated until the end of the experiments (day 16; Figure 1C ). Tunicamycin infusion did not alter heart rate (data not shown). Thus, Tunicamycin-induced systolic hypertension appeared to be independent of heart rates (data not shown).
We also monitored the effects of Tunicamycin on dBP. Similar to sBP, after an initial drop in pressure between days 5 and 7, dBP in Tunicamycin-infused mice gradually increased at day 8 and reached maximal at day 13 ( Figure 1C ). The dBP remained significantly elevated at day 16 ( Figure 1C ).
4-PBA Abolishes Tunicamycin-Enhanced sBP and dBP in Mice
To establish the causal link of ER stress and hypertension, we treated Tunicamycin-infused mice with ER chaperone 4-PBA. As shown in Figure 1C and 1D, 4-PBA alone did not affect either sBP or dBP in vehicle-treated WT mice. 4-PBA alone did not alter heart rate in mice (data not shown). Interestingly, 4-PBA administration partially but significantly reduced Tunicamycin-induced sBP increase ( Figure 1C) . In contrast to a partial reduction of sBP, 4-PBA completely normalized dBP in Tunicamycin-infused mice ( Figure 1D ), suggesting that ER stress might preferentially cause the elevation of dBP in vivo.
Exposure of Isolated Aortic Rings to Tunicamycin or MG132 Induces ER Stress Ex Vivo
Next, we assayed whether exposure of isolated aortas to Tunicamycin or MG132 caused ER stress in isolated aortas. To this end, isolated aortas were exposed to Tunicamycin or MG132 with or without the addition of 4-PBA or AICAR. As expected, exposure of aortic rings to either Tunicamycin or MG132 markedly increased the levels of p-elf2α, GRP78, and XBP-1s (Figure 2A and 2B ). In addition, 4-PBA attenuated the levels of p-elf2α, GRP78, and XBP-1s enhanced by Tunicamycin or MG132 (Figure 2A and 2B ). Furthermore, preincubation of aortic rings with AICAR, an AMPK activator, abolished ER stress markers enhanced by Tunicamycin or MG132 (Figure 2A and 2B). These results suggest that AICAR and 4-PBA can effectively lower Tunicamycin-and MG132-induced ER stress in vessels.
ER Stress Inducers Accentuate PE-Induced Vasoconstriction Ex Vivo
dBP is mainly determined by the contractility of peripheral resistant arteries. Increased vasocontractility was found to be similar in the aortas and peripheral resistant arteries from AMPKα2 -/mice. 26 Although mouse aortas are not resistant arteries, we used isolated mouse aortas to assay the effects of ER stress inducers on vasocontractility. As depicted in Figure  2C and 2D, PE caused vasoconstriction in a dose-dependent manner. Incubation of aortic rings with either Tunicamycin or MG132 markedly accentuated PE-induced vasoconstriction ( Figure 2C and 2D ). In addition, coincubation with 4-PBA, an ER stress inhibitor, markedly lowered vasoconstriction enhanced by either 4-PBA or MG132 ( Figure 2C and 2D), implying that ER stress potentiates PE-dependent vasoconstriction.
AICAR Attenuates ER Stress-Accentuated Vasoconstriction
Because AICAR reduced Tunicamycin-and MG132-induced ER stress (Figure 2A and 2B), we hypothesized that AICAR might suppress Tunicamycin-enhanced vasoconstriction in response to PE. As shown in Figure 2C , AICAR abrogated the Tunicamycin-enhanced PE response in isolated aortas. Similarly, AICAR abolished MG132-potentiated PE-induced vasoconstriction ( Figure 2D ).
ER Stress-Enhanced PE-Induced Vasoconstriction Is Endothelium Independent
We had reported previously that AMPK activation suppressed ER stress in endothelial cells. 17, 18 It was important to determine whether ER stress in the endothelium contributed to ER stress-enhanced vasoconstriction in response to PE. To this end, endothelium-denuded aortas were incubated with Tunicamycin before its incubation with PE. As shown in Figure 2E , Tunicamycin-induced PE response was comparable between endothelium-intact aortas and the endotheliumdenuded aortas.
One of the most important factors in maintaining vasotone is nitric oxide (NO). We next investigated the effects of Tunicamycin in the aortas isolated from endothelial NO synthase (eNOS)-deficient mice (eNOS -/-). PE caused a dose-dependent vasoconstriction in the aortas from WT and eNOS -/mice ( Figure 2F ). Exposure of mouse aortas to Tunicamycin markedly increased PE-triggered vasoconstriction in WT and eNOS -/mice ( Figure 2F ), suggesting that ER stress in the endothelium was not involved in Tunicamycin-enhanced PE response. 
ER Stress-Dependent Phosphorylation of Myosin Light Chain in Isolated Aortas
The phosphorylation of myosin light chain (MLC) facilitates the stimulation of myosin ATPase activity by α-actin, leading to cross-bridge cycling and contraction. Thus, it was important to evaluate the effects of ER stress on MLC phosphorylation in isolated aortas. As expected, exposure of isolated aortic rings to Tunicamycin or MG132 markedly increased the levels of phosphorylated (p-)MLC ( Figure 2G and 2H) . Importantly, inhibition of ER stress with 4-PBA abolished the effects of Tunicamycin and MG132 on p-MLC ( Figure  2G and 2H), implying that ER stress mediated the increase of p-MLC. Similar to 4-PBA, AICAR attenuated Tunicamycinor MG132-mediated MLC phosphorylation ( Figure 2G and 2H), suggesting that the effects of AICAR on p-MLC are likely via its inhibition on ER stress.
ER Stress Triggers MLC Phosphorylation in Cultured VSMCs
Because vasocontractility is mainly dictated by VSMCs in vasculature, we next determined whether Tunicamycin or MG132 altered p-MLC in cultured VSMCs. As depicted in Figure 2I , Tunicamycin-enhanced MLC phosphorylation occurred at 3 hours and reached maximal at 12 hours ( Figure  2I ). Similarly, MG132 (500 nmol/L) markedly increased the levels of p-MLC at 2 hours and reached a peak at 12 hours ( Figure 2J ). Importantly, pretreatment of tauroursodeoxycholic acid (TUDCA) or 4-PBA for 2 hours attenuated the effects of Tunicamycin or MG132 on MLC phosphorylation in VSMCs ( Figure 2L and 2K ), suggesting an ER stress-dependent MLC phosphorylation in VSMCs.
AMPK Activation Suppresses ER Stress-Enhanced MLC Phosphorylation in VSMCs
We next determined whether AMPK activators, AICAR and metformin, altered ER stress-induced MLC phosphorylation. As depicted in Figure 3A and 3B, treatment with AICAR or metformin markedly reduced Tunicamycin-induced ER stress in cultured VSMCs. Pretreatment with metformin or AICAR for 1 hour attenuated the levels of p-elf2α, Grp78, and XBP-1s ( Figure 3A and 3B) . The maximal effect of metformin was observed at 2 hours. The maximal effect of AICAR was seen at 4 hours after the treatment (data not shown). Concomitantly, AICAR and metformin also markedly suppressed Tunicamycin-or MG132-enhanced MLC phosphorylation in VSMCs ( Figure 3C and 3D) . p-MLC is regulated through myosin light-chain kinase and myosin light-chain phosphatase. Thus, it was interesting to determine whether ER stress affected MLC phosphatase. Because RhoA and Rho kinase, components of the Ca 2+ -independent pathway for maintaining muscle contraction, inhibited MLC phosphatase activity, we further determined whether RhoA kinase was required for ER stressenhanced MLC phosphorylation in VSMCs. Cultured VSMCs were stimulated with Tunicamycin with or without 4-PBA, and GTP-bound RhoA was pulled down and Western blotted with the antibody against RhoA antibody. Short incubation of Tunicamycin (<6 hours) did not alter RhoA-GTP contents ( Figure 3E) . Thus, increased p-MLC was before RhoA activation by Tunicamycin. Longer incubation of Tunicamycin (>6 hours) markedly increased the level of RhoA-GTP without altering total Rho A levels, which were partially attenuated by 4-PBA ( Figure 3F ). Taken together, RhoA activation unlikely contributed to early phosphorylation of p-MLC caused by ER stress.
AMPK Activation Suppresses ER Stress-Enhanced Intracellular Calcium but Increases Calcium in ER
Previous studies 31, 32 had demonstrated that elevation of intracellular Ca 2+ is a common mechanism for aberrant ER stress and unfolded protein response activation. Importantly, p-MLC is regulated through MLC kinase via intracellular Ca 2+ elevation, Therefore, we tested whether inhibition of AMPK increased ER stress by altering intracellular Ca 2+ levels. As expected, Tunicamycin caused a rapid increase of cytosolic Ca 2+ in parallel with a reduction of Ca 2+ in ER ( Figure 4A ); pretreatment with AICAR or metformin significantly reduced Tunicamycin-induced rise of intracellular Ca 2+ , whereas they increased the levels of Ca 2+ in ER ( Figure 4A ). Consistently, inhibition of AMPK with compound C markedly increased the levels of intracellular Ca 2+ ( Figure 4B) .
To exclude the potential off-target effects of compound C, we assayed the intracellular Ca 2+ concentration in VSMCs isolated from WT and AMPKα2 -/mice. As depicted in Figure  4C , intracellular Ca 2+ levels in AMPKα2 -/-VSMCs were significantly elevated when compared with VSMCs isolated from WT mice ( Figure 4C ). Consistently, ER Ca 2+ levels were significantly lower in VSMCs from AMPKα2 -/mice, as compared with those obtained from WT mice (P<0.05; Figure 4C ). Finally, free cytoplasmic calcium [Ca 2+ ] I/relative fluorescence units were significantly elevated in VSMCs from AMPKα2 -/mice when compared with those from WT mice ( Figure 4D ). Taken together, these results suggest that reduction of AMPKα2 activity increased the intracellular Ca 2+ levels but exhibited reduced levels of Ca 2+ in the ER.
Aberrant ER Stress Contributes to Elevated Levels of MLC Phosphorylation in AMPKα2 -/-Mice
It was interesting to determine whether aberrant ER stress altered the MLC phosphorylation in AMPKα2 -/mice in vivo. As depicted in Figure 5A , AMPKα2 -/mice exhibited higher levels of p-elf2α (Ser51), Grp78, and XBPs than those from WT mice, which were attenuated by the pretreatment of TUDCA or 4-PBA. Importantly, the levels of p-MLC were higher in AMPKα2 -/mice than those in WT mice ( Figure  5B ). Furthermore, inhibition of ER stress with TUDCA or 4-PBA normalized the levels of p-MLC in AMPKα2 -/mice, although it did not alter the levels of p-MLC in WT mice ( Figure 5A and 5B) . These results suggested that ER stress in AMPKα2 -/mice caused increased MLC phosphorylation.
Inhibition of ER Stress Normalizes PE-Induced Vasoconstriction in AMPKα2 -/-Mice
We next determined whether aberrant ER stress was responsible for increased PE-induced vasoconstriction in AMPKα2 -/mice. As depicted in Figure 5C and 5D, PE caused greater vasoconstriction responses in AMPKα2 -/mice than those from WT mice. Incubation of 4-PBA or TUDCA alone did not alter the vasoconstriction response in WT aortas (data not shown). However, either 4-PBA or TUDCA markedly suppressed PE-induced vasoconstriction ( Figure 5C and 5D ), suggesting that heightened ER stress was likely responsible for increased vasoconstriction responses in AMPKα2 -/mice.
Inhibition of ER Stress Lowers High Blood Pressure in AMPKα2 -/-Mice In Vivo
We had found previously that genetic deletion of AMPKα2 led to elevated blood pressure in C57BL6 mice 26 and that this also caused an elevated level of ER stress and disturbed intracellular Ca 2+ balance. We therefore reasoned that inhibition of ER stress might lower high blood pressure observed in AMPKα2 -/mice. To this end, WT and AMPKα2 -/mice were administered 4-PBA for 2 weeks. As expected, the levels of ER stress markers (p-elf2α, XBP-1s, and KDEL) were higher in AMPKα2 -/mice when compared with WT mice ( Figure  6A ). In addition, 4-PBA markedly decreased the levels of ER stress markers (p-elf2α, XBP-1s, and KDEL) in AMPKα2 -/mice in vivo ( Figure 6A ). As shown in Figure 6B and 6C, 4-PBA significantly lowered both sBP and dBP in AMPKα2 -/mice in vivo.
Inhibition of ER Stress Lowers High Blood Pressure in Mice Infused With Angiotensin II In Vivo
The renin-angiotensin system is essential in maintaining blood pressure. Thus, it was important to determine whether ER stress contributes to angiotensin II (Ang II)-induced hypertension in vivo. As reported previously, 33 Ang II infusion caused an increase in sBP and dBP in WT animals ( Figure 7A and  7B) . As expected, 4-PBA lowered both sBP and dBP at day 7 after Ang II infusion ( Figure 7A and 7B) . The effects of 4-PBA reached a maximal effect at day 11 for both parameters ( Figure 7A and 7B) . In contrast, administration of Ang II in AMPKα2 -/mice resulted in a more marked rise in sBP and dBP ( Figure 7C and 7D) . Similarly, 4-PBA cotreatment in AMPKα2 -/mice resulted in a partial normalization of both sBP and dBP starting at day 7. The effects of 4-PBA on both parameters reached maximal at day 11( Figure 7C and 7D). The effects of 4-PBA in AMPKα2 -/mice were smaller than those in WT mice ( Figure 7E and 7F) . The pressures in AMPKα2 -/mice remained ≈5to 10-mm|Hg higher than controls (4-PBA only; Figure 7C and 7D). These results might be explained by heightened ER stress levels in AMPKα2 -/mice.
Discussion
In this study, we have provided the first evidence that ER stress can significantly elevate blood pressure in vivo and that this effect is ameliorated by AMPK activation. ER stress inducer Tunicamycin increases VSMC phosphorylation of MLC, vasocontractility, and blood pressure. Importantly, chronic administration of ER stress chaperone lowers blood pressure in Ang II-infused mice and AMPKα2 -/mice, suggesting that AMPK inhibition-triggered ER stress in VSMCs might play a causative role in the development and progression of high blood pressure in vivo. Figure 5 . Inhibition of aberrant endoplasmic reticulum (ER) stress normalizes vasoconstriction and myosin light chain (MLC) phosphorylation in AMP-activated protein kinase (AMPK) α2 -/mice. Vessels were pretreated with tauroursodeoxycholic acid (TUDCA) or 4-phenyl butyric acid (4-PBA) for 2 hours. A, Immunoblots of P-elf2α (Ser51), Grp78, and spliced XBP-1 in aortas from mice treated with 4-PBA or TUDCA for 3 weeks. The blot is a representative of 3 blots from ≥3 mice. B, Immunoblots of phosphorylated (p-) MLC in aortas from mice treated with 4-PBA or TUDCA for 3 weeks. The blot is a representative of 3 blots from ≥3 mice. C, Vessel contraction in isolated aortas from wild-type (WT) and AMPKα2 -/mice pretreated with 4-PBA for 2 hours; n=6. D, Effects of TUDCA on vessel contraction in isolated vessels from WT and AMPKα2 -/mice; n=6. The data from C and D were analyzed by using the 2-way ANOVA for repeated measures followed by Bonferroni post hoc test.
Blood pressure is maintained by both cardiac output and peripheral vascular resistance. 32 ER stress might cause hypertension by increasing cardiac output and peripheral vascular resistance. Indeed, increased sBP and dBP were found in mice infused with Tunicamycin and in AMPKα2 -/mice in which aberrant ER stress was observed. Importantly, administration of ER chaperones significantly reduced both sBP and dBP in AMPKα2 -/mice and in mice infused with Ang II. The most provocative finding in this study is that ER stress causes abnormal contractility of vascular smooth muscle, resulting in increased blood pressure. This conclusion is supported by the following findings. First, induction of ER stress by Tunicamycin or MG132 markedly increased PE-mediated vasoconstriction, which was further confirmed by increased detection of p-MLC. These effects of Tunicamycin were ablated by ER chaperones such as 4-PBA. Second, acute infusion of Tunicamycin caused a marked elevation of both sBP and dBP. Coadministration of 4-PBA, which alone had no effect on blood pressure, abolished the effects of Tunicamycin, suggesting an ER stress-dependent elevation of blood pressure. Third, coinfusion of 4-PBA significantly lowered both sBP and dBP in mice infused with Ang II, suggesting that ER stress might, at least partially, contribute to high blood pressure caused by Ang II infusion, a well-characterized model of hypertension. Finally, AMPKα2 -/mice, which exhibited aberrant levels of ER stress, were hypertensive with increased contractility. Importantly, administration of 4-PBA and TUDCA markedly lowered sBP and dBP in AMPKα2 -/mice but not in WT mice, providing further support that ER stress is essential in maintaining normal blood pressure. Indeed, aberrant ER stress is also reported in hypertensive patients ,32,33 or animals 34 with metabolic syndrome and in hypertensive animals such as high salt intake-induced hypertensive rats 35 and Ang II-infused hypertensive mice. 36 Taken together, our results strongly suggest that 4-PBA via ER stress inhibition inhibited vascular contractility and high blood pressure. However, our results have not established a causative relation among ER stress, vascular contractility, and high blood pressure. Although we consider that this possibility is low, we cannot exclude the possibility that 4-PBA might have myriad effects on blood pressure that are independent of ER stress or vascular contractility. Further study on a causative effect of ER stress, vascular contractility, and blood pressure is warranted.
Recent studies have found that activation of AMPK is an important defensive response to ER stress in cardiomyocytes. 37, 38 Our own previous studies have also found that activation of AMPK exerts protective effects in endothelial cells by suppressing ER stress in the genesis of atherosclerosis. 17, 18 Here we have extended these observations in VSMCs and found that AMPK, at least in part via its suppression on ER stress in VSMCs, maintains normal vascular tones. AMPKα2 mice exhibited increased vasoconstriction to PE and exhibited high blood pressure, which were sensitive to ER chaperones. The molecular mechanisms by which AMPK inhibits vascular contractility and lowers blood pressure might be multiple. In this study, we found that ER stress promotes the phosphorylation of MLC, likely via the reduction of intracellular Ca 2+ . This finding is consistent with our previous study, which demonstrates that AMPK functions as a physiological suppressor of ER stress by maintaining sarco/ ER Ca 2+ -ATPase activity and intracellular Ca 2+ homeostasis in endothelial cells. 18 In addition, AMPK has been shown to lower blood pressure by improving NO bioactivity and endothelial cell function. 26 This has been mechanistically attributed to increasing NO release by enhancing the phosphorylation and activation of eNOS at Ser1177 and Ser633 and by blocking NO inactivation by reactive oxygen species. 26 Although the contribution of the AMPK-eNOS-ER stress axis in maintaining normal blood pressure remains to be investigated, the present study provides new evidence in support of an ER stress-AMPK-MLC axis that partly explains the hypertensive phenotype of mice deficient in AMPKα2, thereby establishing a novel role of AMPK in the regulation of blood pressure.
Clinical data strongly support that AMPK might be a therapeutic target in treating hypertension. Metformin, one of mostly used antidiabetic drugs, is a potent activator of AMPK. AMPK-lowering effects are supported by blood-lowering effects of metformin. [39] [40] [41] In women with polycystic ovarian syndrome, metformin reduced sBP, hyperinsulinemia, and insulin resistance and facilitated menstrual regulation and pregnancy. 42 Metformin also improves blood pressure in hypertensive and obese women. 43 In summary, our results have demonstrated that AMPK is essential in maintaining ER function in VSMCs, and aberrant ER stress might play a causative role in the development and progression of hypertension.
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Figure 7.
Suppression of endoplasmic reticulum (ER) stresses by 4-phenyl butyric acid (4-PBA) lowers angiotensin II (Ang II)-induced high blood pressure. The systolic blood pressure and diastolic blood pressure were monitored by telemetry system. Means±SEMs for each group (n=12) are presented for both AMP-activated protein kinase (AMPK) α2 -/and wild-type (WT) mice. *P<0.05 Ang II vs 4-PBA or 4-PBA plus Ang II. A and B, WT mice were treated with 4-PBA for 2 weeks after Ang II treatment for 5 days; n=10 in each group. *P<0.05 Ang II vs 4-PBA or 4-PBA plus Ang II. C and D, AMPKα2 -/mice were treated with 4-PBA for 2 weeks after Ang II treatment for 5 days; n=10 in each group. *P<0.05 Ang II vs 4-PBA or 4-PBA plus Ang II. E and F, Systolic and diastolic blood pressures in AMPKα2 -/and WT mice treated with or without 4-PBA. *P<0.05 Ang II vs 4-PBA, #P<0.05 Ang II vs 4-PBA plus Ang II, †P<0.05 Ang II in WT vs Ang II in AMPKα2 -/-, and ‡P<0.05 Ang II vs Ang II plus 4-PBA. The data were analyzed by using the 2-way ANOVA for repeated measures followed by Bonferroni post hoc test.
